These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 16932285)

  • 1. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
    Colao A; Di Sarno A; Guerra E; De Leo M; Mentone A; Lombardi G
    Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):200-10. PubMed ID: 16932285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
    Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
    Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
    Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperprolactinemia: pathophysiology and management.
    Verhelst J; Abs R
    Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
    Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.
    Webster J; Piscitelli G; Polli A; Ferrari CI; Ismail I; Scanlon MF
    N Engl J Med; 1994 Oct; 331(14):904-9. PubMed ID: 7915824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine agonists and pituitary tumor shrinkage.
    Bevan JS; Webster J; Burke CW; Scanlon MF
    Endocr Rev; 1992 May; 13(2):220-40. PubMed ID: 1352243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
    Colao A; Sarno AD; Cappabianca P; Briganti F; Pivonello R; Somma CD; Faggiano A; Biondi B; Lombardi G
    Eur J Endocrinol; 2003 Mar; 148(3):325-31. PubMed ID: 12611613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.
    Biller BM; Molitch ME; Vance ML; Cannistraro KB; Davis KR; Simons JA; Schoenfelder JR; Klibanski A
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2338-43. PubMed ID: 8964874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of prolactinomas: a survey of physicians from the Middle East and North Africa.
    Beshyah SA; Sherif IH; Chentli F; Hamrahian A; Khalil AB; Raef H; El-Fikki M; Jambart S
    Pituitary; 2017 Apr; 20(2):231-240. PubMed ID: 27783196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
    Iyer P; Molitch ME
    Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactinoma in pregnancy.
    Molitch ME
    Best Pract Res Clin Endocrinol Metab; 2011 Dec; 25(6):885-96. PubMed ID: 22115164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
    Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
    Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
    Hamilton DK; Vance ML; Boulos PT; Laws ER
    Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.